Term ended Feb 22, 2024 · Medium confidence
20-year base term ended Jun 30, 2021
Why Medium: A parent in the chain could not be resolved.
Held by Seraph Biotech Consulting, LLC
Filed Jul 27, 2004 as application 10/900,451 · Granted Oct 15, 2013
Base term plus 967 days of patent term adjustment (USPTO delay)
Today
Term ended Feb 22, 2024
2001
2026
Clock starts
Jun 30, 2001
Jun 30, 2001
Term ended
Feb 22, 2024
Feb 22, 2024
Granted
Oct 15, 2013
Oct 15, 2013
base term
patent term adjustment
after the term ends
fee events
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
967
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
None
Terminal disclaimer
No disclaimer on this record.
3 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
30
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term runs 967 days past its 20-year base term on prosecution delay. All three maintenance fees were paid, so no fee lapse ended it. Confidence: Medium. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Jun 30, 2001, when application 09/896,897, the earliest non-provisional in its chain, was filed (this one was filed Jul 27, 2004); a parent in its chain could not be resolved (the next row) | Jun 30, 2021 | High confidence |
| Continuity chain | A parent in the chain could not be resolved | dated from this application's own claim | Medium confidence |
| Patent term adjustment | +967 days, USPTO patent term adjustment record | Feb 22, 2024 | High confidence |
| Terminal disclaimer cap | None on record | no cap applied | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 3 of 3 maintenance fees paid | term ended | High confidence |
| Computed term end | The steps above, in order | Feb 22, 2024 | Medium confidence |
This family
| Application 09/896,897 | Abandoned not computed | not computed |
| Application 10/693,481 | Abandoned not computed | not computed |
| US 9,790,621 | Term ended no later than Nov 2021 | no later than Nov 2021 |
| Application 10/900,452 | Abandoned not computed | not computed |
| US 9,309,563 | Term ended no later than Oct 2026 | no later than Oct 2026 |
| US 8,557,522 | this patent Feb 2024 | Feb 2024 |
| US 9,234,234 | Term ended no later than Dec 2023 | no later than Dec 2023 |
| US 9,163,280 | Term ended no later than Jan 2025 | no later than Jan 2025 |
8 of 30 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Oct 12, 2015 Reel 36771, frame 115 | Rabbani, Elazar; Stavrianopoulos, Jannis G.; Donegan, James J.; Coleman, Jack | Enzo Life Sciences, Inc. | Assignment of Assignor's Interest |
| Apr 3, 2023 Reel 63239, frame 103 | Enzo Life Sciences, Inc.; Enzo Clinical Labs, Inc.; Enzo Biochem, Inc.; Enzo Life Sciences U.S. Holding Corp. | Gemino Healthcare Finance, LLC D/B/A SLR Healthcare ABL | Security Interest |
| Jul 24, 2023 Reel 64369, frame 31 | Gemino Healthcare Finance, LLC D/B/A SLR Healthcare ABL | Enzo Biochem, Inc.; Enzo Clinical Labs, Inc.; Enzo Life Sciences U.S. Holding Corp.; Enzo Life Sciences, Inc. | Release of Security Interest |
| Jul 24, 2023 reel/frame not recorded | Gemino Healthcare Finance, LLC D/B/A SLR Healthcare ABL | Enzo Biochem, Inc. | Release of Security Interest |
| Jul 24, 2023 reel/frame not recorded | Gemino Healthcare Finance, LLC D/B/A SLR Healthcare ABL | Enzo Clinical Labs, Inc. | Release of Security Interest |
| Jul 24, 2023 reel/frame not recorded | Gemino Healthcare Finance, LLC D/B/A SLR Healthcare ABL | Enzo Life Sciences U.S. Holding Corp. | Release of Security Interest |
| Jul 24, 2023 reel/frame not recorded | Gemino Healthcare Finance, LLC D/B/A SLR Healthcare ABL | Enzo Life Sciences, Inc. | Release of Security Interest |
| Jul 9, 2026 Reel 75219, frame 465 | Enzo Biochem, Inc.; Enzo Life Sciences, Inc.; Enzo Therapeutics, Inc. | Seraph Biotech Consulting, LLC | Assignment of Assignor's Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
What's changing
Note
The 967 days of patent term adjustment (USPTO delay) are read from the USPTO record, not recalculated by us
Citations
1
later US patent cites this one
That is below the median of utility patents granted in 2013 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.